Free tool
FAERS Monitor: Xromi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216593 or its brand name (Xromi, Hydroxyurea). Reports on generic versions are filed under their own applications.
Reports
14,936
Serious
10,721
72% of reports
Hospitalization
5,227
Death reported
2,099
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,805
- sickle cell anaemia with crisis1,246
- fatigue1,160
- diarrhoea1,111
- nausea1,007
- headache834
- death786
- product dose omission issue771
- drug ineffective745
- haemoglobin decreased682
- anaemia676
- pain651
- pyrexia596
- dyspnoea586
- asthenia561
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 99 |
| 2006 | 141 |
| 2007 | 140 |
| 2008 | 141 |
| 2009 | 151 |
| 2010 | 187 |
| 2011 | 251 |
| 2012 | 340 |
| 2013 | 219 |
| 2014 | 379 |
| 2015 | 465 |
| 2016 | 718 |
| 2017 | 873 |
| 2018 | 1,087 |
| 2019 | 958 |
| 2020 | 1,256 |
| 2021 | 1,456 |
| 2022 | 1,589 |
| 2023 | 1,439 |
| 2024 | 1,143 |
| 2025 | 1,058 |
| 2026 | 755 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,223 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sickle cell anaemia with crisisSignal | 1,246 | 120.8 | 114.3 | 136,338 |
| haemoglobin decreasedSignal | 682 | 9.4 | 8.7 | 5,108 |
| anaemiaSignal | 676 | 5.0 | 4.6 | 2,175 |
| product dose omission issueSignal | 771 | 3.7 | 3.5 | 1,533 |
| off label useSignal | 1,805 | 2.9 | 2.8 | 2,349 |
| pyrexiaSignal | 596 | 2.4 | 2.2 | 507 |
| diarrhoeaSignal | 1,111 | 2.4 | 2.3 | 958 |
| astheniaSignal | 561 | 2.1 | 1.9 | 329 |
| fatigueSignal | 1,160 | 2.1 | 2.0 | 692 |
| headache | 834 | 1.9 | 1.8 | 349 |
| nausea | 1,007 | 1.8 | 1.7 | 365 |
| pain | 651 | 1.5 | 1.4 | 109 |
| dyspnoea | 586 | 1.5 | 1.3 | 86 |
| death | 786 | 1.3 | 1.2 | 51 |
| drug ineffective | 745 | 0.8 | 0.7 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.